Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections

被引:97
作者
Lautcnbach, E
Fishman, NO
Bilker, WB
Castiglioni, A
Metlay, JP
Edelstein, PH
Strom, BL
机构
[1] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA
[5] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[6] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[7] Univ Penn, Sch Med, Ctr Res & Educ Therapeut, Philadelphia, PA 19104 USA
关键词
D O I
10.1001/archinte.162.21.2469
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The incidence of fluoroquinolone (FQ) resistance has increased markedly in recent years. Even in the common nosocomial pathogens Escherichia coli and Klebsiella pneumoniae, in which the emergence of FQ resistance was believed to be unlikely, increasing resistance to these agents has been noted. Risk factors for FQ resistance in these pathogens remain unknown. Although FQs are important components of the present antimicrobial arsenal, their continued usefulness is threatened by rising FQ resistance. Objective: To identify risk factors for nosocomial FQ resistance. Methods: A case-control study of hospitalized patients with infections due to FQ-resistant and FQ-susceptible E coli and K pneumoniae occurring between January 1, 1998, and June 30, 1999. Results: We included 123 patients with nosocomial FQ-resistant infections and 70 randomly selected patients with nosocomial FQ-susceptible infections. independent risk factors (adjusted odds ratio [95% confidence interval]) for FQ resistance were (1) recent FQ use (5.25 [1.81-15.26]); (2) residence in a long-term care facility (3.65 [1.64-8.15]); (3) recent aminoglycoside use (8.86 [1.71-45.99]); and (4) older age (1.03 [1.01-1.06]). Conclusions: Recent FQ use, residence in a long-term care facility, recent aminoglycoside use, and older age were all noted to be independent risk factors for FQ resistance among patients with nosocomial E coli and K pneumoniae infections. Efforts should be directed at recognition and modification of these risk factors to curb the rise in FQ resistance and preserve the utility of these agents in the treatment of common nosocomial gram-negative infections.
引用
收藏
页码:2469 / 2477
页数:9
相关论文
共 39 条
[1]   Antimicrobial resistance in isolates from inpatients and outpatients in the united states: Increasing importance of the intensive care unit [J].
Archibald, L ;
Phillips, L ;
Monnet, D ;
McGowan, JE ;
Tenover, F ;
Gaynes, R .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (02) :211-215
[3]   RAPID DEVELOPMENT OF CIPROFLOXACIN RESISTANCE IN METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].
BLUMBERG, HM ;
RIMLAND, D ;
CARROLL, DJ ;
TERRY, P ;
WACHSMUTH, IK .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (06) :1279-1285
[4]   EMERGENCE OF QUINOLONE-RESISTANT ESCHERICHIA-COLI BACTEREMIA IN NEUTROPENIC PATIENTS WITH CANCER WHO HAVE RECEIVED PROPHYLACTIC NORFLOXACIN [J].
CARRATALA, J ;
FERNANDEZSEVILLA, A ;
TUBAU, F ;
CALLIS, M ;
GUDIOL, F .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (03) :557-560
[5]   CROSS-RESISTANCE TO FLUOROQUINOLONES IN MULTIPLE-ANTIBIOTIC-RESISTANT (MAR) ESCHERICHIA-COLI SELECTED BY TETRACYCLINE OR CHLORAMPHENICOL - DECREASED DRUG ACCUMULATION ASSOCIATED WITH MEMBRANE-CHANGES IN ADDITION TO OMPF REDUCTION [J].
COHEN, SP ;
MCMURRY, LM ;
HOOPER, DC ;
WOLFSON, JS ;
LEVY, SB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (08) :1318-1325
[6]   ESCHERICHIA-COLI RESISTANT TO FLUOROQUINOLONES IN PATIENTS WITH CANCER AND NEUTROPENIA [J].
COMETTA, A ;
CALANDRA, T ;
BILLE, J ;
GLAUSER, MP .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (17) :1240-1241
[7]   RISK-FACTORS FOR ACQUISITION OF URINARY-TRACT INFECTIONS CAUSED BY CIPROFLOXACIN RESISTANT ESCHERICHIA-COLI [J].
ENA, J ;
AMADOR, C ;
MARTINEZ, C ;
DELATABLA, VO .
JOURNAL OF UROLOGY, 1995, 153 (01) :117-120
[8]   Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones [J].
Ena, J ;
López-Perezagua, MD ;
Martínez-Peinado, C ;
Cia-Barrio, AD ;
Ruíz-López, I .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 30 (02) :103-107
[9]   Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998 [J].
Fluit, AC ;
Jones, ME ;
Schmitz, FJ ;
Acar, J ;
Gupta, R ;
Verhoef, J .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (03) :454-460
[10]   CDC DEFINITIONS FOR NOSOCOMIAL INFECTIONS, 1988 [J].
GARNER, JS ;
JARVIS, WR ;
EMORI, TG ;
HORAN, TC ;
HUGHES, JM .
AMERICAN JOURNAL OF INFECTION CONTROL, 1988, 16 (03) :128-140